Viewing Study NCT05017012


Ignite Creation Date: 2025-12-26 @ 11:08 AM
Ignite Modification Date: 2025-12-29 @ 8:14 AM
Study NCT ID: NCT05017012
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-12-27
First Post: 2021-08-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module